Concealed Long QT Syndrome: Beta-Blocker Now or Watchful Waiting
A single patient whose genes carry a known risk her own ECG barely shows. The disagreement is about whether the mutation itself is enough reason to start a lifelong medication, or whether her heart should be allowed to declare itself first.
A.F., a 19-year-old woman, is a college sophomore who plays intramural volleyball twice a week and has never had a fainting spell, a racing heart, or anything else that would have put her heart on anyone's radar on its own. She's here because her younger brother collapsed during swim practice this spring and was subsequently diagnosed with Long QT Syndrome Type 1, carrying a KCNQ1 mutation. Cascade genetic testing offered to the whole family found she carries the identical mutation. Her own ECG shows a QTc of 440 milliseconds. The diagnostic threshold in women is 460 milliseconds, so hers is not borderline in any technical sense — it sits inside the normal range, and nothing like her brother's.
LQT1 is the best-characterized of the long QT subtypes, and its cardiac events are strongly tied to exertion and emotional stress — adrenergic surges triggering an arrhythmia in a heart whose repolarization reserve is already reduced by the underlying channel mutation, regardless of how normal the resting ECG looks on a given day. That's the real tension in front of the team: her genotype alone carries documented risk, including the possibility that a cardiac event is a first presentation rather than something that announces itself first with a milder symptom, but she is nineteen, asymptomatic, and being asked to consider a medication she might otherwise take for the rest of her life based on a QTc that a cardiologist reading her ECG cold would not flag at all. This is concealed LQTS, and it is not rare: a substantial minority of confirmed mutation carriers have a resting QTc in the normal range, and a normal tracing does not exclude event risk. Her brother, for context, is recovering well on the same class of medication, and his own QTc before starting therapy was substantially longer than hers — a difference the family has already asked directly what it actually means for her.
A genotype with more certainty than the ECG
I'd start a beta-blocker now, even though her resting QTc reads normal. In LQT1 specifically, event risk tracks with genotype more reliably than with resting QTc alone, and beta-blockers have the strongest evidence of any intervention in this specific subtype for reducing cardiac events. Waiting for a clearer phenotype risks waiting for a first event to be the thing that clarifies it.
I understand the genotype argument, but I'd want more before committing a genuinely asymptomatic nineteen-year-old to a medication she may take for decades. Serial ECGs and an exercise stress test, which in LQT1 can unmask QT prolongation that a resting tracing misses, would tell us more about her actual phenotype before we ask her to start something with real daily tradeoffs — fatigue, exercise limitation, and a lifelong prescription to manage around at every future doctor's visit.
I'm not dismissing the genotype data — I'm asking whether "the evidence supports treating genotype-positive patients" and "we've done enough to characterize this specific patient" are actually the same question, and I don't think they are.
The evidence base specifically for LQT1 is unusually strong on this exact question, which is part of why I'd side with starting therapy now. If this were a different long QT subtype with a less exertion-driven trigger profile, or a subtype where a normal resting QTc carried more reassurance than it does here, I might weigh the waiting argument differently. Her tracing is normal, and I am explicitly not treating it as borderline evidence in favor of therapy — the genotype is doing that work on its own. Given LQT1's documented genotype-driven risk, nadolol is the right choice specifically — a non-selective beta-blocker rather than a beta-1-selective agent, since LQT1 events are triggered by both beta-1 and beta-2 adrenergic stimulation during exertion, and a selective agent leaves real receptor-mediated risk uncovered. The other half of her prescription is a list of what to avoid: QT-prolonging drugs are a lifelong contraindication in this diagnosis, and the ones she is most likely to actually be offered are ordinary — macrolide and fluoroquinolone antibiotics, ondansetron, certain antihistamines and antidepressants. She should carry that list, and treat any illness causing vomiting or diarrhea as a potassium and magnesium problem until proven otherwise.
Nadolol started on the strength of her genotype rather than her ECG, which is normal for a woman and was explicitly not counted as supporting evidence either way, given LQT1's documented genotype-driven risk and the strength of the evidence for beta-blockade in this subtype. A QT-prolonging drug avoid-list placed in her chart and given to her directly. Exercise stress testing still scheduled to further characterize her phenotype, but as a monitoring step rather than a precondition for starting therapy she had already been advised to begin.